44 results about "Pseudotyping" patented technology

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The invention provides BaEV-G envelope glycoprotein, an optimization method of the BaEV-G envelope glycoprotein and an envelope plasmid, a packaging method and a kit which relate to the BaEV-G envelope glycoprotein, and particularly relates to the optimization method of the BaEV-G envelope glycoprotein, chimeric BaEV-G envelope glycoprotein, a lentivirus envelope plasmid, a pseudotyped packaging method of lentivirus and the kit. The BaEV-G envelope glycoprotein and the VSV-G envelope glycoprotein are chimeric to obtain the chimeric BaEV-G envelope glycoprotein, and the properties of lentivirus packaging efficiency, biological activity and the like can be effectively improved.

The invention provides a chimeric envelope glycoprotein, a preparation method thereof and an envelope plasmid, a packaging method and a kit of the chimeric envelope glycoprotein, and particularly relates to a preparation method of the chimeric envelope glycoprotein, the chimeric envelope glycoprotein and a lentivirus envelope plasmid. The invention discloses a pseudotyped packaging method of lentivirus and a kit. The amino acid sequence of the wild type VSV-G envelope glycoprotein is chimeric with the amino acid sequences of other envelope glycoproteins, and compared with the initial wild type envelope glycoprotein, the obtained chimeric envelope glycoprotein can effectively improve the lentivirus packaging efficiency, biological activity and other properties.

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in anti-rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing gene fragments of the ectodomain of the G glycoprotein of the Pasteur strain rabies virus, a linker of 7 amino acids (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the gp64 baculovirus protein, with the arrangement of the sequences in the designed gene cassette being shown in figure 1.

The invention discloses an affinity peptide ligand for separation and purification of a VSV-G pseudotype lentiviral vector and application of the affinity peptide ligand. The affinity peptide ligand contains an amino acid sequence combined with a VSV-G pseudotype lentiviral vector envelope protein; the amino acid sequence is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. A biological raw material solution containing VSV-G pseudotype lentivirus vector components flows into the affinity chromatography medium, and after adsorption and cleaning, a target vector can be collected through a mild elution step; the recovery rate of virus vector particles is 78% or above, the removal rate of Vero host cell impure protein is 90% or above, the double-stranded DNA residue is 48% or below, and the separation effect is very remarkable.

A bispecific monoclonal antibody that specifically binds two distinct epitopes of the Ebola virus (EBOV) glycoprotein (GP) is described. The bispecific antibody is comprised of the antigen binding domains of GP-specific monoclonal antibodies mAb114 and S1-4-A09 (“A09”). The EBOV GP bispecific monoclonal antibody (mAb114×A09 or BiSp107) exhibits synergistic neutralization of pseudotyped virus expressing EBOV GP compared with the neutralization capacity of the combination of the individual parental antibodies. Methods for pre- and post-exposure prophylaxis and treatment are described.

The application provides a BaEV-G envelope glycoprotein, an optimization method thereof, and an envelope plasmid, a packaging method and a kit related to the envelope glyprotein, in particular, relates to an optimization method of a BaEV-G envelope glyprotein, a chimeric BaEV-G envelope glyprotein, a lentivirus envelope plasmid, a lentivirus pseudotyped packaging method and a kit. The BaEV-G envelope glyprotein is chimerized with the VSV-G envelope glyprotein to obtain the chimeric BaEV-G envelope glyprotein, so that the lentivirus packaging efficiency, biological activity and other performances can be effectively improved.

Formulas for use in enhancing the transduction efficiency of lentiviral vector (LV) particles into various target cells are disclosed herein. For example, a formulation for use in enhancing the transduction of paramyxovirus pseudotype lentiviral vector particles into target cells may comprise a cell-permeable peptide (CPP) comprising at least one of Vectofusion-1 or LAH4-C; and poloxamer 407, wherein the concentration of poloxamer 407 is greater than or equal to the concentration of CPP. Additionally, a method of using such formulations to enhance the transduction of LV particles, including particularly in vivo transduction, is disclosed herein.

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

Provided relates to immune cells (e.g., T cells such as γδ T cells) modified to have no or reduced expression and / or function of Ariadne homolog 1 (ARIH1) and further optionally BCL11B, uses thereof (e.g., for treating glioblastoma), and methods of generating thereof. Also provided are methods of modifying γδ T cells using pseudotyped lentiviruses (e.g., BaEV-Rless glycoprotein or BaEV-TR glycoprotein pseudotyped lentiviruses).

To provide methods for selectively modulating the activity of distinct subtypes of cells.SOLUTION: The invention relates to a pseudotyped retrovirus-like particle or retroviral vector comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family, one fused to a cell-targeting domain and the other fused to a functional domain. The invention also relates to the use of the pseudotyped retrovirus-like particle or retroviral vector that selectively modulates a specific subset of cells, in particular activities of specific immune cells. The pseudotyped retrovirus-like particle or retroviral vector is particularly useful for gene therapy, immunotherapy and / or vaccination.SELECTED DRAWING: None

The present invention relates to synthetic designs or chimeric proteins for pseudotyping baculovirus (Autographa californica nuclear polyhedrosis virus) with the rabies virus glycoprotein G (gG) on its surface (Bac::gG-FL), which can be used in rabies vaccine formulations. The chimeric protein is designed from a gene cassette containing genetic fragments from the ectodomain of the Pasteur variant rabies virus glycoprotein G, a 7-amino-acid connector sequence (GGGGSGG), as well as transmembrane (TM) and cytoplasmic (CT) regions of the baculoviral protein gp64, the arrangement of which in the designed gene cassette is shown in Figure 1.

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

The application discloses a CD7 and CD3 double-targeting fusion protein and application thereof. Specifically, the application discloses an isolated fusion protein, which comprises, from N-terminal to C-terminal, (a) an anti-CD7 single-domain antibody (CD7 VHH); (b) an anti-CD3 single-domain antibody (CD3 VHH); and (c) a transmembrane region, which is used for anchoring the fusion protein on a cell membrane or a viral envelope. And a T cell-targeting pseudotyped lentiviral vector based on the fusion protein is constructed. The pseudotyped lentiviral vector of the application can effectively target and activate T cells, and can deliver the expression CAR-containing vector into T cells, thereby effectively activating T cells and enhancing the target killing ability of T cells.

The present invention relates to methods of treating diseases affecting motor function (e.g., motor function affected by diseases, brain and / or spinal cord injuries) using an adeno-associated virus (AAV) gene therapy vector comprising an adeno-associated virus 5 (AAV5) capsid protein and a gene product of interest flanked by an AAV ITR. In particular, the gene therapy vectors of the invention are administered by injection into cerebrospinal fluid (CSF), preferably by lumbar injection and / or injection into the cerebellar medullary pool.

The present disclosure provides recombinant fusogenic proteins comprising a rhabdovirus glycoprotein (G) and a targeting molecule attached to the N-terminus of the rhabdovirus glycoprotein. Further provided are related recombinant polynucleotides, host cells, and pharmaceutical compositions. Recombinant viruses, e.g., recombinant pseudotyped viruses, and cell-derived nanovesicles comprising the recombinant polynucleotides are also provided. Further provided are methods for using the recombinant fusogenic proteins, polynucleotides, viruses, and cell-derived nanovesicles, and / or pharmaceutical compositions thereof, including their use in the treatment of cancer.

Provided is a pseudotyped viral particle, a viral envelope surface thereof comprising immune cell-targeting molecules and / or immune cell-activating molecules. Corresponding targeting molecules are designed on the basis of cell receptors to be targeted, enabling targeting of different types of cells. The application scope is broad, including but not limited to the rapid preparation of CAR-T, CAR-NK, and other immunotherapeutic cells in vitro without the need for sorting and activation, as well as the direct generation of CAR-T, CAR-NK, and other immunotherapeutic cells in vivo.

The present invention relates to pseudotyped lentiviral vectors, in particular lentiviral vectors pseudotyped with a modified severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic applications.

Provided herein are retroviral vector systems for the production of universal pseudotype retroviruses for cell therapy and gene therapy. The vector system comprises an envelope plasmid and a packaging plasmid, wherein at least one of these plasmids encodes a binding moiety that binds directly to a target cell via a cell binding domain or indirectly to a target cell via an antibody binding domain. Also provided are related retrovirus packaging cells, retroviruses, virus-like particles, and methods for their preparation and use in the prevention or treatment of diseases.

This application provides novel viral envelope glycoproteins for pseudotyping viral vectors, novel designs of synthetic antigen receptors (SARs), novel signaling chains for constructing SARs, novel antigen-binding domains, and novel methods for producing SAR-expressing cells. These novel methods and compositions are widely used in cell therapy.

This invention provides a cell line for the efficient propagation of EnvA pseudotyped CVS N2c rabies virus, its preparation method, and its applications. Specifically, this invention provides an N2a cell line with an exogenous expression cassette integrating EnvA and a fluorescent reporter gene into its genome, as well as a method for preparing said cell line. The cell line of this invention can be used to package EnvA pseudotyped CVS N2c rabies virus. The high-titer EnvA pseudotyped rabies virus produced can label and track specific types of neurons for neural pathway research, tracing more information about brain circuits.

The present invention relates to pseudotyped lentiviral vectors, particularly to pseudotyped with a modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic indications.

Provided for herein are pharmaceutical compositions comprising a virus, such as lentiviruses, including pseudotyped lentiviruses and uses thereof. Also provided for herein are methods of purifying and / or concentrating viral vectors and methods of producing sterile compositions, such as, sterile pharmaceutical compositions, wherein the methods can perform steps after passing the viral vector through a protein coated sterile filter. Also provided for herein are methods of using the pharmaceutical compositions.

The present invention provides a pseudotyped retroviral vector particle comprising a) one envelope protein with antigen-binding activity (protein H of a CDV or protein G of a Nipah virus) fused at its ectodomain to a polypeptide that specifically binds to CD4 and / or CD8, and b) one envelope protein with fusion activity (protein F of the virus as the protein H / G), and c) a nucleic acid molecule encoding a transgene, wherein said transgene is a chimeric antigen receptor (CAR) comprising an antigen-specific targeting region, at least one transmembrane domain, and at least one intracellular signaling domain, wherein said antigen-specific targeting region comprises a first antigen binding domain, specific for a first antigen expressed on the surface of a disease-associated target cell and a second antigen binding domain specific for a second antigen expressed on the surface of said disease-associated target cell, and wherein said retroviral vector particle is a lentiviral or gammaretroviral vector particle. Preferentially said antigen binding domains of the CAR are of human origin, more preferentially the CAR has specificity for CD20 and CD19.

The present disclosure provides engineered nucleic acids and compositions thereof that may be used to produce pseudotyped avian rAAV particles. Additionally, the present disclosure provides methods and kits comprising engineered nucleic acids for pseudotyped avian rAAV particle manufacturing. Moreover, the present disclosure provides suitable manufacturing systems. Accordingly, the pseudotyped avian rAAV particles of the disclosure can be isolated and purified at high viral titers that cannot be achieved with conventional rAAV particle production approaches. The pseudotyped avian rAAV particles of the present disclosure are also more suitable for administration in a clinical setting than rAAV particles previously described in the art as they are less immunogenic and, therefore, more compatible for in vivo applications.

The present invention discloses an envelope glycoprotein for packaging and transducing NK cell pseudotyped lentiviral vector and its application; the envelope glycoprotein includes an extracellular region, a transmembrane region and a cytoplasmic region; wherein the amino acid sequence or mutant sequence of the extracellular region is as shown in SEQ ID NO:1 or SEQ ID NO:2; the amino acid sequence or mutant sequence of the transmembrane region is as shown in SEQ ID NO:3 or SEQ ID NO:4; the amino acid sequence or mutant sequence of the cytoplasmic region is as shown in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8. The BaEV envelope glycoprotein mutant replaces VSV-G to package lentiviral pseudovirus, which not only maintains a high virus titer of 7.33E+07 TU / mL, but also can effectively identify NK cells and mediate the virus to enter cells, thereby achieving the purpose of efficiently transfecting NK cells.

This invention belongs to the field of biotechnology, specifically relating to a purification method for BaEV enveloped pseudolentivirus. The purification method includes the following steps: (1) concentrating the clarified BaEV enveloped pseudolentivirus solution, centrifuging, discarding the supernatant, and obtaining a lentivirus precipitate; (2) resuspending the lentivirus precipitate in buffer solution, adding a totipotent nuclease for enzymatic digestion, and obtaining a crude pure sample; (3) purifying the crude pure sample by chromatography to obtain a refined pure sample; (4) concentrating the refined pure sample by ultrafiltration and sterilization to obtain purified BaEV enveloped pseudolentivirus. The BaEV enveloped pseudolentivirus purified using the method of this invention exhibits significantly improved infection titer and titer recovery rate, effectively reducing residual host cell protein, host cell DNA, and endotoxins. The purification method of this invention effectively removes impurities without affecting the activity of the purified lentivirus, and can be used to prepare high-titer and high-purity BaEV pseudolentivirus products.

Designed polypeptide sequences are described, and their use as vaccines against pathogens which cause hemorrhagic fever, such as viruses of the Ebolavirus, Lassa Fever virus and Marburg virus families. The designed sequences include those which comprise the designed Tri-LEMvac vaccine, and the bivalent Lassa virus vaccine. Nucleic acid molecules encoding the polypeptides, as well as vectors, fusion proteins, pseudotyped virus particles, pharmaceutical compositions, combined preparations, cells, and their use as vaccines against viruses of the Ebolavirus, Lassa Fever virus and Marburg virus families are also described.

The present application provides novel viral envelope glycoproteins for viral vector pseudotyping, novel designs for synthetic antigen receptors (SARs), novel signal chains for constructing SAR, novel antigen binding domains, and novel methods for generating SAR expressing cells. These novel methods and compositions have broad applications in cell therapy.

The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.